We target small and microcap biopharmaceuticals companies where our advantage is greatest and mispricing is most intense. These young, often clinical stage companies have little to no institutional attention. Analyst coverage is often done by investment banks with vested interests in the company but often result in material market movements. Retail also comprises the majority of the public ownership and the price resultantly and predictably overweights immaterial information. We place great emphasis on clinical information and our team of young and specialised analysts is made mostly of high ranking Life Sciences students at top UK universities. We hope to be able to change the status-quo of clinical stage equity research, where analyst coverage is really inaccurate due to lacking capacity in the space.Readers looking to access more information about us and our work, should refer to excidium.co.uk
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
#Abeona #Therapeutics #Uncertain #Pivotal #Regulatory #Catalyst #Limited #Upside #ABEO